What Aetna actually changed
Effective September 1, 2026, Aetna — a CVS Health company — expanded its bundled oncology prior authorization program to cover all cancer types for members in eight Medicaid states: Oklahoma, Illinois, Maryland, New Jersey, Virginia, Florida, Kentucky and West Virginia, according to CVS Health and Radiology Business.
The bundles combine medical oncology services — chemotherapy and immunotherapy where appropriate — and radiation oncology with the related high-tech imaging those treatment decisions depend on, namely MRI and CT. Providers using Aetna's Eviti portal can submit one prior-authorization request covering the full course of related care instead of filing separately for each service.
Aetna said it had been seeing providers submit an average of four separate prior authorizations for each member needing cancer treatment. The September expansion builds on an earlier, narrower rollout in which nearly 25% of eligible members had already received a bundled authorization. Aetna's Chief Operating Officer and Medicaid President, Katerina Guerraz, said the goal is that "by approving a broader set of treatments and related services upfront, we're removing barriers that can delay care," per Chain Drug Review.
Medicare and commercial plans are next — in 2027
Aetna has said it expects to extend bundled prior authorization, including the imaging component, to Medicare and commercial members in the first half of 2027, according to StockTitan's coverage of the announcement. That matters because Medicaid managed-care populations are a fraction of Aetna's book of business; a Medicare Advantage and commercial rollout would apply the same bundling logic to a far larger volume of the MRI and CT orders tied to cancer diagnosis and treatment.
The administrative motivation is documented, not just anecdotal. In Aetna's own provider survey, 74% of respondents named administrative burden as the top challenge facing their clinical staff, and 31% pointed to prior authorization management specifically as the largest contributor. 30% believed a technology fix like bundling could save more than an hour a day, and 80% expected to save at least 30 minutes daily, per Aetna's press release via PR Newswire.
A different mechanism than WISeR or H.R. 3514
Aetna's bundling is easy to conflate with other prior-authorization news this year, but it operates on a different lever entirely. It is a single payer restructuring its own approval process — not a federal review pilot and not pending legislation. The table below separates the three.
| Mechanism | Who drives it | Status (Sept. 2026) |
|---|---|---|
| Aetna bundled oncology PA | A single insurer (Aetna/CVS Health), consolidating its own paperwork | Live for Medicaid in 8 states since Sept. 1, 2026; Medicare & commercial targeted H1 2027 |
| WISeR pilot | CMS Innovation Center, using AI-supported review contractors | Running in 6 states (NJ, OH, OK, TX, AZ, WA) since Jan. 1, 2026, through 2031 |
| H.R. 3514 | Congress, via Medicare Advantage prior-auth reform legislation | Advanced by two House committees in 2026; not yet enacted |
WISeR adds a new federal AI-supported review layer to selected traditional Medicare procedures; H.R. 3514 would legislate faster, electronic decisions across Medicare Advantage plans generally. Aetna's program does neither — it is a private insurer deciding, on its own initiative, to approve a course of cancer care and its imaging in one pass rather than several. All three point the same direction: administrative friction around imaging authorization is under pressure to shrink, from three different directions at once.
Why bundling raises the stakes on documentation completeness
A bundled request is a bigger, more consequential submission than four small ones. When medical oncology, radiation oncology and imaging are approved together, the imaging documentation inside that bundle — clinical indication, findings, measurements, comparison to prior studies — has to support a broader treatment plan, not just a single scan. Incomplete or ambiguous imaging reporting inside a bundle risks holding up an entire episode of cancer care, not just one study.
That shifts the practical question for imaging centers and radiology groups from "how fast is our prior-auth desk" to "how fast and how complete is the report leaving our reading room." Three implications follow:
Report completeness becomes an authorization input
A bundled oncology authorization draws on the imaging report as part of a larger clinical picture. Reports that consistently capture findings, measurements and prior comparisons in a structured way give a bundled request the best chance of clearing without a follow-up query.
Turnaround compounds across the bundle
If imaging, radiation oncology and medical oncology are now approved together, a slow imaging report doesn't just delay the scan result — it can delay the whole bundle. Reporting turnaround becomes a shared dependency for other specialties, not an isolated radiology metric.
Structured drafting reduces the query-and-resubmit cycle
A structured, comprehensive report draft that covers the relevant findings the first time reduces the odds that a payer bundle bounces back for clarification — the same logic that applies to prior-authorization documentation generally.
Where this fits with AI CT reporting
Payer-side bundling rewards imaging documentation that is complete and consistent on the first pass, since a query on the imaging portion of a bundle now risks delaying an entire cancer-care approval. A foundation-model approach produces a structured, comprehensive report draft across the full study rather than flagging a single finding, xAID's in-house radiologist reviews every preliminary, and the report reaches the client's reading radiologist ready-to-sign. As bundled and Medicare imaging prior authorization rules expand in 2027, that combination of speed and completeness is exactly what a higher-stakes authorization bundle needs from the reading room.
Frequently asked questions
What did Aetna change about imaging prior authorization?
Effective September 1, 2026, Aetna expanded its bundled oncology prior authorization program to all cancer types for members in eight Medicaid states (Oklahoma, Illinois, Maryland, New Jersey, Virginia, Florida, Kentucky and West Virginia). Instead of submitting separate prior authorizations for medical oncology (chemotherapy, immunotherapy), radiation oncology, and related high-tech imaging such as MRI and CT, providers using the Eviti portal can submit one bundled request covering the full course of related care.
Is Aetna's bundled prior authorization coming to Medicare?
Aetna has said it expects to expand eligibility for bundled oncology prior authorization, including the associated imaging component, to Medicare and commercial members in the first half of 2027. That would extend a payer-driven administrative change to a much larger share of imaging orders tied to cancer diagnosis and treatment.
How is this different from the federal WISeR prior authorization pilot?
They are separate mechanisms with different sponsors. Aetna's bundling program is a single commercial insurer consolidating its own prior-authorization paperwork for oncology-related services, including imaging. WISeR (Wasteful and Inappropriate Service Reduction) is a CMS Innovation Center demonstration that adds AI-supported prior authorization or pre-payment review to 17 selected Medicare Part B services in six states, running from January 2026 through 2031. One reduces paperwork volume for a payer's own members; the other adds a new federal review layer for traditional Medicare.
How many prior authorizations did cancer patients previously require?
Aetna said providers were submitting an average of four separate prior authorizations for each member needing cancer treatment before the bundling program. In the initial rollout, nearly 25% of eligible members had already received a bundled prior authorization by the time the September 2026 expansion was announced.
Source: Aetna's bundled oncology prior authorization expansion, as reported by Radiology Business, CVS Health, PR Newswire, Chain Drug Review and StockTitan. WISeR pilot details per the Society of Interventional Radiology. Figures are rounded as reported.